Main Pharmacogenetic Markers for Methotrexate
Methotrexate toxicity and efficacy vary based on genetic variants in folate metabolism and transport genes. The most common markers tested clinically are:
- MTHFR (rs1801133 C677T and rs1801131 A1298C): Reduce methylenetetrahydrofolate reductase activity, elevating homocysteine and risking toxicity like mucositis or hepatotoxicity. C677T homozygotes (TT) show 30-70% lower enzyme activity.[1]
- SLCO1B1 (rs4149056 c.521T>C): Impairs hepatic uptake, increasing plasma levels and side effects such as gastrointestinal issues. CC genotype raises risk 2-5 fold.[1][2]
- FPGS (rs1544105, rs10025305): Affect folylpolyglutamate synthase, altering intracellular retention. Variants link to reduced efficacy in leukemia and higher relapse risk.[3]
These guide dosing in rheumatoid arthritis, leukemia, and psoriasis, with guidelines from CPIC recommending adjustments for MTHFR and SLCO1B1.[1]
How These Markers Affect Dosing
MTHFR TT carriers often need 20-50% lower doses to avoid myelosuppression. SLCO1B1 C allele prompts plasma monitoring or dose cuts in high-risk patients. FPGS testing is emerging for pediatric ALL, where low-activity variants predict poor response.[2][3]
Why Test for These in Specific Conditions?
In rheumatoid arthritis, MTHFR and SLCO1B1 predict 20-30% of non-responders or toxic cases. For acute lymphoblastic leukemia, they correlate with event-free survival; ABCB1 (rs1045642) also flags efflux issues. Testing reduces discontinuation rates by 15-25%.[1][4]
Less Common but Relevant Markers
- GPRC6A (rs1800716): Influences response in juvenile idiopathic arthritis.
- ATIC (rs4673990): Tied to toxicity in psoriasis.
Guidelines prioritize MTHFR/SLCO1B1; others lack strong evidence for routine use.[3]
Clinical Testing and Guidelines
CPIC and DPWG recommend genotyping MTHFR C677T/A1298C and SLCO1B1 before high-dose therapy. Labs like Mayo Clinic offer panels covering 10+ variants. Cost: $200-500 USD, often covered for oncology.[1][2]
[1]: CPIC Guideline for Methotrexate
[2]: PharmGKB Methotrexate Pathway
[3]: Frontiers in Pharmacology Review (2021)
[4]: Clinical Pharmacogenetics Implementation Consortium Update